You are here

Developing a Nrf2 activator for the treatment of COPD

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41HL122004-01A1
Agency Tracking Number: R41HL122004
Amount: $224,896.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NHLBI
Solicitation Number: PA13-235
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
BALTIMORE, MD 21205-1503
United States
DUNS: 961692493
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (301) 461-7934
Business Contact
Phone: (301) 461-7934
Research Institution
733 N. Broadway, Suite 117 Edward D. Miller Research Building
BALTIMORE, MD 21205-1832
United States

 () -
 Nonprofit college or university

DESCRIPTION (provided by applicant): Chronic obstructive pulmonary disease (COPD) is a major cause of mortality and morbidity worldwide. In the US alone, the disease afflicts ~13 million people and is the third-leading cause of death. Cigarette smoking isthe primary risk factor for COPD, initiating a persistent and progressive inflammatory immune response. Respiratory infections and pollutants can exacerbate COPD symptoms, often leading to pulmonary tissue injury. Currently, there are no approved medicinesthat can slow or stop the progression of COPD. Symptoms such as coughing and shortness of breath are typically treated using bronchodilators. Despite the key role of inflammation in the pathogenesis of COPD, treatment with anti-inflammatory corticosteroiddrugs provides limited therapeutic benefit. Corticosteroid treatment reduces symptoms in only about 20% of COPD patients without improving survival or slowing disease progression. New treatments that inhibit inflammation and improve corticosteroid re

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government